Methods of administering peptides that bind to the erythropoietin receptor
November 3, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethod for the purification of erythropoietin and erythropoietin compositions DNA sequences encoding erythropoietin Erythropoietin (EPO) peptides Recombinant DNA endoding an erythropoietin receptor Homogeneous erythropoietin compositions and methods of using same In-vitro method for determining a surreptitious use of exogenous erythropoiesis stimulating agents by a normal living subject Enhancer for the antianemia effect of erythropoietin and method of augmenting the antianemia effect of erythropoietin Proteinaceous compositions having an activity on erythropoiesis Patent #: 5482924 InventorsAssigneeApplicationNo. 484631 filed on 06/07/1995US Classes:514/2, Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI435/69.1, Recombinant DNA technique included in method of making a protein or polypeptide514/8, Glycoprotein (carbohydrate containing)514/12, 25 or more peptide repeating units in known peptide chain structure514/13, 16 to 24 peptide repeating units in known peptide chain514/14, 12 to 15 peptide repeating units in known peptide chain514/159 to 11 peptide repeating units in known peptide chainExaminersPrimary: Walsh, StephenAssistant: Kemmerer, Elizabeth Attorney, Agent or FirmForeign Patent References
International ClassesA61K 038/04C07K 007/04 C12N 015/00 AbstractPeptides of 10 to 40 or more amino acid residues in length and having the sequence X3 X4 X5 GPX6 TWX7 X8 (SEQ ID NO:252) where each amino acid is indicated by standard one letter abbreviation; X3 is C; X4 is R, H, L, or W; X5 is M, F, or I; X6 is independently selected from any one of the 20 genetically coded L-amino acids; X7 is D, E, I, L, or V; and X8 is C, which bind and activate the erythropoietin receptor (EPO-R) or otherwise act as an EPO agonist, and methods for their use.Other References
Field of SearchPeptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAIGlycoprotein (carbohydrate containing) 25 or more peptide repeating units in known peptide chain structure 16 to 24 peptide repeating units in known peptide chain 12 to 15 peptide repeating units in known peptide chain 9 to 11 peptide repeating units in known peptide chain Recombinant DNA technique included in method of making a protein or polypeptide |
| ||||||||||||||
